Behind Wuxi AppTec's "High Growth" Q3 Report: Non-Recurring Gains Account for 80% of Profits, Domestic Business Stagnates

Biotech Stocks Surge: Wuxi Bio and Wuxi Apptec Lead Gains

JPMorgan Increases Stake in WUXI APPTEC (02359) by Approximately 736,509 Shares at HK$102.49 per Share

Wuxi Apptec's Capital Conundrum Amid GLP-1 Boom

BRIEF-Blackrock's Long Position In H-Shares Of Wuxi Apptec Increases To 5.48% On Nov 5 - HKEX

BlackRock's Long Position in H-Shares of WuXi AppTec Increases to 5.48% on Nov 5 From 4.80% - HKEX

Wuxi Apptec's Earnings "Big Rebound": Did Li Ge Show Off Financial Tricks?

CCB International Raises WUXI APPTEC (02359) Target Price to HK$131, Maintains "Outperform" Rating

BOCI Raises WUXI APPTEC (02359) Target Price to HK$127 on Strong Q3 Results

Oct 29 Shareholding Changes: Hangzhou Oxygen Plans to Increase Stake, While 11 Stocks Including Wuxi Apptec Plan Reductions (Table)

BRIEF-Wuxi AppTec's Shareholders To Cut 2% A-Shares

Refile-WuXi AppTec Says Shareholders Plan to Unload up to Combined 2% a-Shares in Co (Clarifies Shareholders to Cut a-Shares)

WuXi AppTec Says Shareholders Plan to Unload up to Combined 2% Stakes in Co

Performance, Efficiency, and Strategy in Harmony: WUXI APPTEC (02359) CRDMO Model Flourishes in Q3 2025

BRIEF-NEOM Signs Strategic MoU With Wuxi AppTec To Advance Saudi's Biotechnology Sector

WuXi AppTec - Signs Strategic Mous With Neom and Saudi Ministry of Health

WuXi AppTec Signs Strategic MoUs with NEOM and Saudi Ministry of Health to Localize Pharma Industry

Goldman Sachs: WUXI APPTEC (02359) Q3 Earnings Beat Expectations, Focus on New Order Momentum and Clinical CRO Business; Target Price HK$109.6

WuXi AppTec Keeps Bull on 3Q Earnings Beat -- Market Talk

Wuxi Apptec Sells Two More Subsidiaries for 2.8 Billion Yuan in Strategic Shift